Lumos Medical Wins First Prize at 2026 Eyennovation International Summit; Files IPO Prospectus

Mar 31, 2026 11:55 CST Updated 11:55

Purevision Medical

Developer of Ophthalmic Disease Treatment Products

Recently, Danlu Capital's invested companyPurevision Medical Wins First Prize in Project Roadshow at "2026 Eyennovation International Summit"Demonstrates its exceptional innovation and clinical transformation capabilities in the field of ophthalmic minimally invasive devices. As a technology-based startup focusing on innovative ophthalmic devices, Purevision Medical continuously promotes original technologies to go global with its profound background in medical-engineering integration.

｜Purevision Medical Wins First Prize in Project Roadshow

Meeting Details

This summit was hosted byInternational Alliance of Ophthalmic Innovation (IAOI)Hosted, bringing together more than 100 top ophthalmology experts from home and abroad, over 80 speakers, and an on-site attendance of more than 300 participants. The summit gathers global top experts to engage in in-depth exchanges on ophthalmic innovation and investment and financing, making it an international platform with significant influence in China. The award won by Purevision Medical further confirms its competitive advantage in the high-end ophthalmic device field.

During the summit,Wang Yan, Vice General Manager of Purevision MedicalInvited to participate in a roundtable discussion, sharing the globalization path of China's original technology in the field of medical device exports, demonstrating Purevision Medical's active role in international perspective and strategic layout.

Purevision Medical

Purevision Medical, founded in October 2020, is a technology-based startup focusing on innovative ophthalmic medical devices and is a national high-tech enterprise. The company concentrates on minimally invasive and precise treatments for eye diseases such as glaucoma, adhering to the core concept of "integration of medicine and engineering, clinically driven." Relying on a strong background in the combination of medical and engineering expertise, the company has built comprehensive capabilities from identifying clinical pain points to achieving engineering closed-loop solutions.Its independently developed original AqueFish® Glaucoma Drainage Device significantly enhances the safety and effectiveness of surgery, filling the gap in China's high-end minimally invasive glaucoma device field.

Purevision Medical is committed to building a globally leading innovative ophthalmic minimally invasive treatment platform, guided by clinical needs and technological innovation at its core, continuously promoting China-originated ophthalmic devices to the global market.

Danlu Perspective

As an early investor in Purevision Medical, Danlu Capital has witnessed the solid footsteps along this journey. We are thrilled to see Purevision Medical win the first prize in the project pitch at the 2026 Eyennovation International Summit and actively participate in the roundtable discussion on "Medical Device Export". This not only represents the industry's high recognition of its original technical strength and clinical transformation capabilities but also confirms our initial judgment — in the high-barrier track of ophthalmic minimally invasive surgery, Purevision Medical possesses the potential to move from source innovation to the global market, thanks to its unique "medical-engineering integration" gene and solid engineering capabilities.

In the future, Danlu Capital will continue to firmly support Purevision Medical in深耕 the ophthalmology field, accelerate the落地 of innovative成果, and help China's ophthalmic innovation shine on the international stage.

Note: Some content and images in the article are from the Internet. If there is any infringement, please inform us to delete.

Source of information and images: Official Account @Purevision Medical

Danlu Capital